StreetInsider.com News Articles

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

Tue, 17 Feb 2026 09:15:00 -0500

Access the “What This Means” segment here

LA JOLLA, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it participated in a Virtual Investor “What This Means” segment.

As part of the segment, Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI Bio, discussed important

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

Tue, 17 Feb 2026 09:15:00 -0500

Access the “What This Means” segment here

As part of the segment, Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI Bio, discussed important

Form SCHEDULE 13G/A GRI Bio, Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Fri, 13 Feb 2026 16:43:00 -0500

si-local-file:///var/storage/secattach/20260213/26001372.html

Form SCHEDULE 13G/A GRI Bio, Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Fri, 13 Feb 2026 16:43:00 -0500

si-local-file:///var/storage/secattach/20260213/26001372.html

Form SCHEDULE 13G/A GRI Bio, Inc. Filed by: Lincoln Alternative Strategies LLC

Tue, 10 Feb 2026 14:11:00 -0500

si-local-file:///var/storage/secattach/20260210/25974609.html

Form SCHEDULE 13G/A GRI Bio, Inc. Filed by: Lincoln Alternative Strategies LLC

Tue, 10 Feb 2026 14:11:00 -0500

si-local-file:///var/storage/secattach/20260210/25974609.html

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Thu, 05 Feb 2026 09:15:00 -0500

– Live video webcast on Wednesday, February 11^th at 1:00 PM EST

LA JOLLA, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026.

Details of the presentation are as follows:
Date and Time: Wednesday, February 11, 2026 at 1:00

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Thu, 05 Feb 2026 09:15:00 -0500

– Live video webcast on Wednesday, February 11^th at 1:00 PM EST

Details of the presentation are as follows:
Date and Time: Wednesday, February 11, 2026 at 1:00

Form 8-K GRI Bio, Inc. For: Feb 04

Wed, 04 Feb 2026 08:49:00 -0500

si-local-file:///var/storage/secattach/20260204/25943862.html

Form 8-K GRI Bio, Inc. For: Feb 04

Wed, 04 Feb 2026 08:49:00 -0500

si-local-file:///var/storage/secattach/20260204/25943862.html

GRI Bio raises $6.5 million, extends cash runway into Q1 2027

Wed, 04 Feb 2026 08:47:41 -0500

GRI Bio Inc. (NASDAQ: GRI) reported $8.2 million in cash and cash equivalents as of December 31, 2025, and raised an additional $6.5 million in gross proceeds in January 2026 through its At The Market offering program.

The biotechnology company stated its current cash position will fund planned operations into the first quarter of 2027. The company raised approximately $14.5 million in gross proceeds across December 2025 and January 2026.

GRI Bio reported a net loss of $12 million for the year ended December 31, 2025. Research and development expenses increased to $6.8 million in 2025 from $3.8 million in 2024, primarily

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

Wed, 04 Feb 2026 08:45:00 -0500

Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026

Balance sheet strengthened to fund operations into Q1 2027

Strong Phase 2a clinical data for GRI-0621 in idiopathic pulmonary fibrosis reinforce clinical proof-of-concept and therapeutic differentiation

GRI-0803 focused on autoimmune indications with high unmet need advancing through IND-enabling activities

LA JOLLA, CA, Feb. 04, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

Wed, 04 Feb 2026 08:45:00 -0500

Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026

Balance sheet strengthened to fund operations into Q1 2027

Strong Phase 2a clinical data for GRI-0621 in idiopathic pulmonary fibrosis reinforce clinical proof-of-concept and therapeutic differentiation

GRI-0803 focused on autoimmune indications with high unmet need advancing through IND-enabling activities

LA JOLLA, CA, Feb. 04, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing

Form EFFECT GRI Bio, Inc.

Mon, 02 Feb 2026 06:08:00 -0500

si-local-file:///var/storage/secattach/20260202/25926544.html

Form EFFECT GRI Bio, Inc.

Mon, 02 Feb 2026 06:08:00 -0500

si-local-file:///var/storage/secattach/20260202/25926544.html

Form 10-K GRI Bio, Inc. For: Dec 31

Fri, 30 Jan 2026 07:34:00 -0500

si-local-file:///var/storage/secattach/20260130/25919813.html

Form 10-K GRI Bio, Inc. For: Dec 31

Fri, 30 Jan 2026 07:34:00 -0500

si-local-file:///var/storage/secattach/20260130/25919813.html

GRI Bio, Inc (GRI) files $250M mixed shelf

Fri, 30 Jan 2026 06:08:32 -0500

GRI Bio, Inc (NASDAQ: GRI) has files $250,000,000 mixed shelf of:

Common Stock
Preferred Stock
Debt Securities
Warrants
Units

GRI Bio, Inc (GRI) files $250M mixed shelf

Fri, 30 Jan 2026 06:08:32 -0500

GRI Bio, Inc (NASDAQ: GRI) has files $250,000,000 mixed shelf of:

Common Stock
Preferred Stock
Debt Securities
Warrants
Units

Form S-3 GRI Bio, Inc.